Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 May;80(5-6):918–921. doi: 10.1038/sj.bjc.6690442

Expression of CD44 by rhabdomyosarcoma: a new prognostic marker?

G Humphrey 1, D L Hazel 1, K MacLennan 2, I Lewis 1
PMCID: PMC2362272  PMID: 10360676

Abstract

The expression pattern of CD44 standard and variant isoforms are prognostically significant in a number of malignancies. The aim of this study was to evaluate the role of the standard isoform of CD44 in predicting the clinical behaviour of rhabdomyosarcoma. Immunohistochemical analysis of CD44 was undertaken using a panel of antibodies recognizing the three core domains of the CD44 molecule. Labelling was repeated in triplicate and reported blind with respect to histological type and outcome. Tumours were characterized as positive in more than 60% of tumour cells labelled and negative if less than 40% of tumour cells labelled. Tumours with 40–60% of tumour cells labelling were considered indeterminate. Eleven of 20 favourable histology tumours were positive for CD44 compared with one of seven unfavourable tumours (P = 0.07). Eleven of 12 patients with CD44-positive tumours are alive in first remission compared with five of 15 CD44-negative tumours (P = 0.001). Expression of CD44 correlates directly with prognosis; however, larger studies are required so that multivariate analysis can be undertaken. © 1999 Cancer Research Campaign

Keywords: CD44, rhabdomyosarcoma, prognosis

Full Text

The Full Text of this article is available as a PDF (278.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abbasi A. M., Chester K. A., Talbot I. C., Macpherson A. S., Boxer G., Forbes A., Malcolm A. D., Begent R. H. CD44 is associated with proliferation in normal and neoplastic human colorectal epithelial cells. Eur J Cancer. 1993;29A(14):1995–2002. doi: 10.1016/0959-8049(93)90461-n. [DOI] [PubMed] [Google Scholar]
  2. Anstee D. J., Gardner B., Spring F. A., Holmes C. H., Simpson K. L., Parsons S. F., Mallinson G., Yousaf S. M., Judson P. A. New monoclonal antibodies in CD44 and CD58: their use to quantify CD44 and CD58 on normal human erythrocytes and to compare the distribution of CD44 and CD58 in human tissues. Immunology. 1991 Oct;74(2):197–205. [PMC free article] [PubMed] [Google Scholar]
  3. Arch R., Wirth K., Hofmann M., Ponta H., Matzku S., Herrlich P., Zöller M. Participation in normal immune responses of a metastasis-inducing splice variant of CD44. Science. 1992 Jul 31;257(5070):682–685. doi: 10.1126/science.1496383. [DOI] [PubMed] [Google Scholar]
  4. Birch M., Mitchell S., Hart I. R. Isolation and characterization of human melanoma cell variants expressing high and low levels of CD44. Cancer Res. 1991 Dec 15;51(24):6660–6667. [PubMed] [Google Scholar]
  5. Christiansen H., Sahin K., Berthold F., Hero B., Terpe H. J., Lampert F. Comparison of DNA aneuploidy, chromosome 1 abnormalities, MYCN amplification and CD44 expression as prognostic factors in neuroblastoma. Eur J Cancer. 1995;31A(4):541–544. doi: 10.1016/0959-8049(95)00030-m. [DOI] [PubMed] [Google Scholar]
  6. Culty M., Miyake K., Kincade P. W., Sikorski E., Butcher E. C., Underhill C., Silorski E. The hyaluronate receptor is a member of the CD44 (H-CAM) family of cell surface glycoproteins. J Cell Biol. 1990 Dec;111(6 Pt 1):2765–2774. doi: 10.1083/jcb.111.6.2765. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Dall P., Heider K. H., Hekele A., von Minckwitz G., Kaufmann M., Ponta H., Herrlich P. Surface protein expression and messenger RNA-splicing analysis of CD44 in uterine cervical cancer and normal cervical epithelium. Cancer Res. 1994 Jul 1;54(13):3337–3341. [PubMed] [Google Scholar]
  8. Dias P., Kumar P., Marsden H. B., Gattamaneni H. R., Heighway J., Kumar S. N-myc gene is amplified in alveolar rhabdomyosarcomas (RMS) but not in embryonal RMS. Int J Cancer. 1990 Apr 15;45(4):593–596. doi: 10.1002/ijc.2910450403. [DOI] [PubMed] [Google Scholar]
  9. Driman D., Thorner P. S., Greenberg M. L., Chilton-MacNeill S., Squire J. MYCN gene amplification in rhabdomyosarcoma. Cancer. 1994 Apr 15;73(8):2231–2237. doi: 10.1002/1097-0142(19940415)73:8<2231::aid-cncr2820730832>3.0.co;2-e. [DOI] [PubMed] [Google Scholar]
  10. Favrot M. C., Combaret V., Lasset C. CD44--a new prognostic marker for neuroblastoma. N Engl J Med. 1993 Dec 23;329(26):1965–1965. doi: 10.1056/NEJM199312233292615. [DOI] [PubMed] [Google Scholar]
  11. Forsberg U. H., Ala-Kapee M. M., Jalkanen S., Andersson L. C., Schröder J. The gene for human lymphocyte homing receptor is located on chromosome 11. Eur J Immunol. 1989 Feb;19(2):409–412. doi: 10.1002/eji.1830190228. [DOI] [PubMed] [Google Scholar]
  12. Fujita N., Yaegashi N., Ide Y., Sato S., Nakamura M., Ishiwata I., Yajima A. Expression of CD44 in normal human versus tumor endometrial tissues: possible implication of reduced expression of CD44 in lymph-vascular space involvement of cancer cells. Cancer Res. 1994 Jul 15;54(14):3922–3928. [PubMed] [Google Scholar]
  13. Gross N., Beck D., Beretta C., Jackson D., Perruisseau G. CD44 expression and modulation on human neuroblastoma tumours and cell lines. Eur J Cancer. 1995;31A(4):471–475. doi: 10.1016/0959-8049(95)00029-i. [DOI] [PubMed] [Google Scholar]
  14. Gross N., Beretta C., Peruisseau G., Jackson D., Simmons D., Beck D. CD44H expression by human neuroblastoma cells: relation to MYCN amplification and lineage differentiation. Cancer Res. 1994 Aug 1;54(15):4238–4242. [PubMed] [Google Scholar]
  15. Günthert U., Hofmann M., Rudy W., Reber S., Zöller M., Haussmann I., Matzku S., Wenzel A., Ponta H., Herrlich P. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell. 1991 Apr 5;65(1):13–24. doi: 10.1016/0092-8674(91)90403-l. [DOI] [PubMed] [Google Scholar]
  16. Harwood C. A., Green M. A., Cook M. G. CD44 expression in melanocytic lesions: a marker of malignant progression? Br J Dermatol. 1996 Dec;135(6):876–882. doi: 10.1046/j.1365-2133.1996.d01-1089.x. [DOI] [PubMed] [Google Scholar]
  17. Heider K. H., Dämmrich J., Skroch-Angel P., Müller-Hermelink H. K., Vollmers H. P., Herrlich P., Ponta H. Differential expression of CD44 splice variants in intestinal- and diffuse-type human gastric carcinomas and normal gastric mucosa. Cancer Res. 1993 Sep 15;53(18):4197–4203. [PubMed] [Google Scholar]
  18. Heider K. H., Hofmann M., Hors E., van den Berg F., Ponta H., Herrlich P., Pals S. T. A human homologue of the rat metastasis-associated variant of CD44 is expressed in colorectal carcinomas and adenomatous polyps. J Cell Biol. 1993 Jan;120(1):227–233. doi: 10.1083/jcb.120.1.227. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Herrlich P., Zöller M., Pals S. T., Ponta H. CD44 splice variants: metastases meet lymphocytes. Immunol Today. 1993 Aug;14(8):395–399. doi: 10.1016/0167-5699(93)90141-7. [DOI] [PubMed] [Google Scholar]
  20. Jackson D. G., Buckley J., Bell J. I. Multiple variants of the human lymphocyte homing receptor CD44 generated by insertions at a single site in the extracellular domain. J Biol Chem. 1992 Mar 5;267(7):4732–4739. [PubMed] [Google Scholar]
  21. Joensuu H., Klemi P. J., Toikkanen S., Jalkanen S. Glycoprotein CD44 expression and its association with survival in breast cancer. Am J Pathol. 1993 Sep;143(3):867–874. [PMC free article] [PubMed] [Google Scholar]
  22. Koopman G., Heider K. H., Horst E., Adolf G. R., van den Berg F., Ponta H., Herrlich P., Pals S. T. Activated human lymphocytes and aggressive non-Hodgkin's lymphomas express a homologue of the rat metastasis-associated variant of CD44. J Exp Med. 1993 Apr 1;177(4):897–904. doi: 10.1084/jem.177.4.897. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Lesley J., Hyman R., Kincade P. W. CD44 and its interaction with extracellular matrix. Adv Immunol. 1993;54:271–335. doi: 10.1016/s0065-2776(08)60537-4. [DOI] [PubMed] [Google Scholar]
  24. Mackay C. R., Terpe H. J., Stauder R., Marston W. L., Stark H., Günthert U. Expression and modulation of CD44 variant isoforms in humans. J Cell Biol. 1994 Jan;124(1-2):71–82. doi: 10.1083/jcb.124.1.71. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Maillet M. W., Robinson R. A., Burgart L. J. Genomic alterations in sarcomas: a histologic correlative study with use of oncogene panels. Mod Pathol. 1992 Jul;5(4):410–414. [PubMed] [Google Scholar]
  26. Matsumura Y., Hanbury D., Smith J., Tarin D. Non-invasive detection of malignancy by identification of unusual CD44 gene activity in exfoliated cancer cells. BMJ. 1994 Mar 5;308(6929):619–624. doi: 10.1136/bmj.308.6929.619. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Matsumura Y., Tarin D. Significance of CD44 gene products for cancer diagnosis and disease evaluation. Lancet. 1992 Oct 31;340(8827):1053–1058. doi: 10.1016/0140-6736(92)93077-z. [DOI] [PubMed] [Google Scholar]
  28. Mayer B., Jauch K. W., Günthert U., Figdor C. G., Schildberg F. W., Funke I., Johnson J. P. De-novo expression of CD44 and survival in gastric cancer. Lancet. 1993 Oct 23;342(8878):1019–1022. doi: 10.1016/0140-6736(93)92879-x. [DOI] [PubMed] [Google Scholar]
  29. Nagabhushan M., Pretlow T. G., Guo Y. J., Amini S. B., Pretlow T. P., Sy M. S. Altered expression of CD44 in human prostate cancer during progression. Am J Clin Pathol. 1996 Nov;106(5):647–651. doi: 10.1093/ajcp/106.5.647. [DOI] [PubMed] [Google Scholar]
  30. Newton W. A., Jr, Gehan E. A., Webber B. L., Marsden H. B., van Unnik A. J., Hamoudi A. B., Tsokos M. G., Shimada H., Harms D., Schmidt D. Classification of rhabdomyosarcomas and related sarcomas. Pathologic aspects and proposal for a new classification--an Intergroup Rhabdomyosarcoma Study. Cancer. 1995 Sep 15;76(6):1073–1085. doi: 10.1002/1097-0142(19950915)76:6<1073::aid-cncr2820760624>3.0.co;2-l. [DOI] [PubMed] [Google Scholar]
  31. Penno M. B., August J. T., Baylin S. B., Mabry M., Linnoila R. I., Lee V. S., Croteau D., Yang X. L., Rosada C. Expression of CD44 in human lung tumors. Cancer Res. 1994 Mar 1;54(5):1381–1387. [PubMed] [Google Scholar]
  32. Picker L. J., Nakache M., Butcher E. C. Monoclonal antibodies to human lymphocyte homing receptors define a novel class of adhesion molecules on diverse cell types. J Cell Biol. 1989 Aug;109(2):927–937. doi: 10.1083/jcb.109.2.927. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Salmi M., Grön-Virta K., Sointu P., Grenman R., Kalimo H., Jalkanen S. Regulated expression of exon v6 containing isoforms of CD44 in man: downregulation during malignant transformation of tumors of squamocellular origin. J Cell Biol. 1993 Jul;122(2):431–442. doi: 10.1083/jcb.122.2.431. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Saxon B. R., Byard R. W., Han P. Cellular expression of adhesion factors in childhood rhabdomyosarcoma. Pediatr Pathol Lab Med. 1997 Mar-Apr;17(2):259–266. [PubMed] [Google Scholar]
  35. Screaton G. R., Bell M. V., Jackson D. G., Cornelis F. B., Gerth U., Bell J. I. Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc Natl Acad Sci U S A. 1992 Dec 15;89(24):12160–12164. doi: 10.1073/pnas.89.24.12160. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Shtivelman E., Bishop J. M. Expression of CD44 is repressed in neuroblastoma cells. Mol Cell Biol. 1991 Nov;11(11):5446–5453. doi: 10.1128/mcb.11.11.5446. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Southgate J., Trejdosiewicz L. K., Smith B., Selby P. J. Patterns of splice variant CD44 expression by normal human urothelium in situ and in vitro and by bladder-carcinoma cell lines. Int J Cancer. 1995 Aug 9;62(4):449–456. doi: 10.1002/ijc.2910620415. [DOI] [PubMed] [Google Scholar]
  38. Sy M. S., Guo Y. J., Stamenkovic I. Distinct effects of two CD44 isoforms on tumor growth in vivo. J Exp Med. 1991 Oct 1;174(4):859–866. doi: 10.1084/jem.174.4.859. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Tanabe K. K., Ellis L. M., Saya H. Expression of CD44R1 adhesion molecule in colon carcinomas and metastases. Lancet. 1993 Mar 20;341(8847):725–726. doi: 10.1016/0140-6736(93)90490-8. [DOI] [PubMed] [Google Scholar]
  40. Terpe H. J., Christiansen H., Gonzalez M., Berthold F., Lampert F. Differentiation and prognosis of neuroblastoma in correlation to the expression of CD44s. Eur J Cancer. 1995;31A(4):549–552. doi: 10.1016/0959-8049(95)00061-m. [DOI] [PubMed] [Google Scholar]
  41. Tsuda H., Shimosato Y., Upton M. P., Yokota J., Terada M., Ohira M., Sugimura T., Hirohashi S. Retrospective study on amplification of N-myc and c-myc genes in pediatric solid tumors and its association with prognosis and tumor differentiation. Lab Invest. 1988 Sep;59(3):321–327. [PubMed] [Google Scholar]
  42. Wielenga V. J., Heider K. H., Offerhaus G. J., Adolf G. R., van den Berg F. M., Ponta H., Herrlich P., Pals S. T. Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression. Cancer Res. 1993 Oct 15;53(20):4754–4756. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES